Contribution of the GSTP1 gene polymorphism to the development of osteosarcoma in a Chinese population

Abstract

ABSTRACT. We conducted a case-control study to investigate the associations between GSTT1, GSTM1, and GSTP1 gene polymorphisms and development of osteosarcoma in a Chinese population. Between January 2013 and February 2015, 153 patients diagnosed with osteosarcoma and 252 control subjects were enrolled in the current study from the Orthopedic Hospital of the Second Hospital of Jilin University. The GSTM1, GSTT1, and GSTP1 gene polymorphisms were detected by polymerase chain reaction coupled with restriction fragment length polymorphism analysis. As determined by a multiple-logistic regression analysis, the Val/Val genotype of GSTP1 was associated with a significantly increased risk of osteosarcoma compared to that of the Ile/Ile genotype, with an odds ratio (OR) = 3.39, and a 95% confidence interval (CI) = 1.45-8.13. Moreover, the Ile/Val+Val/Val genotype of GSTP1 was correlated with a marginally significant increased risk of osteosarcoma compared to that of the Ile/Ile genotype (OR = 1.65, 95%CI = 1.08-2.53). However, we did not find any significant associations between the GSTM1 and GSTT1 gene polymorphisms and osteosarcoma risk. In conclusion, our results suggest that the GSTP1 gene polymorphism is associated with an increased risk of osteosarcoma, whereas the GSTM1 and GSTT1 gene polymorphisms may not influence the development of this cancer.

Association of GSTM1, GSTT1, GSTM3, and GSTP1 Genes Polymorphisms with Susceptibility to Osteosarcoma: a Case- Control Study and Meta-Analysis

“…Four selected GSTs polymorphisms (GSTM1, GSTT1, GSTM3, and GSTP1) were tested in this study. Genotyping was carried out using the Restriction Fragment Length Polymorphism of polymerase chain reaction (PCR-RFLP) method as described previously (Li et al 2015;Qu et al 2016).…”

“…A flow chart of the literature search is shown in Figure 1. Finally, a total of 24 case-control studies in nine publications (Barnette et al, 2004;Li et al, 2015;Lu et al, 2011;Peters et al, 2000;Qu et al, 2016;Salinas-Souza et al, 2010;Yang et al, 2012;Zhang et al, 2012) including 2,405 osteosarcoma cases and 3,293 controls were included in the present meta-analysis. The characteristics of the 24 eligible studies are presented in Table 1 and 2.…”

“…Many studies have shown that genetic variation in GSTs enzymes, including GSTP1 A313G (rs1695, Ile105Val) and homozygous deletions of the active alleles of GSTM1 and GSTT1 (null genotype) have a role in susceptibility to osteosarcoma (Barnette et al, 2004;Li et al, 2015;Lu et al, 2011;Peters et al, 2000;Qu et al, 2016;Salinas-Souza et al, 2010;Yang et al, 2012;Zhang et al, 2012). However, case-control studies undertaken in different populations gave controversial results, due to small sample size or other causes.…”

HIF-2α affects proliferation and apoptosis of MG-63 osteosarcoma cells through MAPK signaling

“…This makes osteosarcoma a significant threat to human health. In China, it is estimated that the number of patients with osteosarcoma may reach 2–5 million and that the annual medical expenditure for this disease may amount to 300–500 million yuan (12). Drugs for targeted therapy of osteosarcoma are still under development (13).…”

Associations between inflammatory gene polymorphisms (TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G, TGF-β1 29T/C, IL-6 174G/C and IL-10 1082A/G) and susceptibility to osteosarcoma: a meta-analysis and literature review

“…Copy number gains at chromosomes 1p, 1q, 6p, 8q and 17p, and copy number losses at chromosomes 3q, 6q, 9, 10, 13, 17p and 18q have been reported by many research groups, including the systematic review regarding the role of genes in the etiology of OS conducted by Martin et al [ 8 ]. In addition, more gene polymorphisms have been found to play a key role in the etiology and development of OS, highlighting the importance of gene polymorphisms in this disease [ 19 – 22 ].…”